Dutch study tracks COVID-19 drugs in real world to find who benefits most
NCT ID NCT05195060
First seen Jan 11, 2026 · Last updated Apr 29, 2026 · Updated 16 times
Summary
This study followed over 1,100 adults in the Netherlands who received monoclonal antibodies or antiviral pills for COVID-19. Researchers collected blood samples and nasal swabs over 90 days to measure how the virus and the body's immune response changed during treatment. The goal was to understand which patients benefit most and to watch for new viral variants or side effects. Participants did not receive any experimental treatment, but the findings may help doctors use these drugs more effectively in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amsterdam University Medical Centre
Amsterdam, North Holland, 1105 AZ, Netherlands
-
Amsterdam University Medical centre - VUMC
Amsterdam, North Holland, 1081 HV, Netherlands
-
Leiden universitair medisch centrum
Leiden, 2333ZA, Netherlands
-
Radboud Universitair Medisch Centrum
Nijmegen, 6525GA, Netherlands
Conditions
Explore the condition pages connected to this study.